Ramanujan’s elegant formulas for calculating pi, developed more than a century ago, have unexpectedly resurfaced at the heart of modern physics. Researchers at IISc discovered that the same ...

Financial vulnerability in the UK continues to rise. More than six in ten adults now display at least one characteristic that could increase their risk if firms fail to respond appropriately, and ...

If you have a savings account, you might want to know how much you’ll earn in interest for parking your cash there. Fortunately, calculating interest on a savings account is not as tough as you might ...

A 41-acre cabin compound in Pennsylvania is bringing new meaning to the concept of a weekend retreat, offering up a collection of cozy homes surrounded by a spread of picturesque land for just $1.3 ...

Forty-six oral medications communly used in hospitalized patients were evaluated. Study investigators identified these medications as the formulary medications most frequently prescribed in the ...

Continuous biomanufacturing is mature enough to use commercially for a range of products, manufacturing scales, and global geographies. That’s the conclusion of Sarfaraz Niazi, PhD, adjunct professor ...

Katy French and Danielle Perez show how to make bold, renter-friendly textured art with easy joint compound methods anyone can try. ‘Enough is Enough’: New Gun Law Sparks Lawsuit He’s advised 50+ ...

NYK has begun what it calls “continuous” use of low-carbon bio-LNG fuel on its LNG-powered car carriers. The bunkers are being provided by Dutch group Titan Supply at the port of Zeebrugge in Belgium.

With another hot Texas summer underway, the threat of dehydration always looms. Though this condition can range from inconvenient to life-threatening, it's tough to track. "Dehydration is a silent ...

A $10,000 investment in SCHD at its 2011 launch, with dividends reinvested, would be worth approximately $49,000 today, reflecting a 12% annualized return and a dramatic boost from compounding. Yield ...

Fed-batch and batch bioprocessing still dominate monoclonal antibody (mAb) production, but that must change if mAbs are to become economically viable therapeutic options. Current production techniques ...